GFAP and Alzheimer disease: Parallels between changes in plasma p-tau species and glial fibrillary acidic protein (GFAP) species in recent anti-amyloid antibody trials (phase II in donanemab and phase III in lecanemab) raise the possibility that astroglial activation may mediate the interaction between Aβ plaques and soluble p-tau accumulation in AD.